PainReform Ltd. (PRFX) Income Statement Analysis

See more : 4SC AG (VSC.DE) Income Statement Analysis – Financial Results

Complete financial analysis of PainReform Ltd. (PRFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PainReform Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

PainReform Ltd. (PRFX)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.painreform.com

About PainReform Ltd.

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017
Revenue	0.00	86.00K	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	15.00K	15.00K	7.00K	0.00	1.00K	0.00	0.00
Gross Profit	-15.00K	71.00K	-7.00K	0.00	-1.00K	0.00	0.00
Gross Profit Ratio	0.00%	82.56%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	6.04M	4.42M	2.86M	354.00K	136.00K	223.00K	504.00K
General & Administrative	3.48M	4.45M	4.35M	1.32M	553.00K	277.00K	376.00K
Selling & Marketing	66.00K	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	3.55M	4.45M	4.35M	1.32M	553.00K	277.00K	376.00K
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	9.58M	8.87M	7.21M	1.67M	689.00K	500.00K	877.00K
Cost & Expenses	9.58M	8.87M	7.21M	1.67M	689.00K	500.00K	877.00K
Interest Income	406.00K	160.00K	0.00	1.05K	588.00	0.00	245.00K
Interest Expense	384.00K	61.00K	10.00K	987.00K	541.00K	324.00K	0.00
Depreciation & Amortization	15.00K	15.00K	7.00K	1.00K	1.00K	500.00K	880.00K
EBITDA	-9.57M	-8.85M	-7.20M	-1.67M	-688.00K	0.00	-1.21M
EBITDA Ratio	0.00%	-10,124.42%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-9.58M	-8.87M	-7.21M	-1.67M	-689.00K	-500.00K	-880.00K
Operating Income Ratio	0.00%	-10,312.79%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	248.00K	86.00K	-32.00K	-2.16M	-590.00K	-328.00K	-242.00K
Income Before Tax	-9.34M	-8.78M	-7.24M	-3.83M	-1.28M	-828.00K	-1.12M
Income Before Tax Ratio	0.00%	-10,212.79%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	8.00K	9.00K	6.00K	220.00K	541.00K	4.00K	-242.00K
Net Income	-9.34M	-8.79M	-7.25M	-4.05M	-1.82M	-828.00K	-2.09M
Net Income Ratio	0.00%	-10,223.26%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-42.86	-8.25	-7.38	-3.46	-1.96	-1.43	-36.67
EPS Diluted	-42.83	-8.25	-7.38	-3.46	-1.96	-1.43	-36.25
Weighted Avg Shares Out	218.00K	1.07M	981.22K	1.17M	930.79K	579.55K	57.00K
Weighted Avg Shares Out (Dil)	218.15K	1.07M	981.22K	1.17M	930.79K	579.55K	57.66K

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

January 7, 2021globenewswire.com

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright...